Arecor Therapeutics plc Share Price

Equities

AREC

GB00BMWLM973

Biotechnology & Medical Research

Market Closed - London S.E. 16:35:20 29/05/2024 BST 5-day change 1st Jan Change
158.5 GBX -0.94% Intraday chart for Arecor Therapeutics plc 0.00% -13.15%

Financials

Sales 2023 4.57M 5.81M 457M Sales 2024 * 7.49M 9.51M 749M Capitalization 48.54M 61.66M 4.85B
Net income 2023 -8M -10.16M -800M Net income 2024 * -5M -6.35M -500M EV / Sales 2023 12.2 x
Net cash position 2023 * 6.16M 7.83M 616M Net cash position 2024 * 1.46M 1.86M 146M EV / Sales 2024 * 6.29 x
P/E ratio 2023
-6.52 x
P/E ratio 2024 *
-9.06 x
Employees 51
Yield 2023 *
-
Yield 2024 *
-
Free-Float 48.52%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Arecor Therapeutics plc

1 day-0.94%
Current month+16.12%
1 month+16.12%
3 months+15.27%
6 months-14.78%
Current year-13.15%
More quotes
1 week
157.00
Extreme 157
170.00
1 month
124.30
Extreme 124.3
170.00
Current year
124.30
Extreme 124.3
184.00
1 year
124.30
Extreme 124.3
260.00
3 years
124.30
Extreme 124.3
472.00
5 years
124.30
Extreme 124.3
472.00
10 years
124.30
Extreme 124.3
472.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 -
Director of Finance/CFO 65 31/12/18
Chief Tech/Sci/R&D Officer - 31/07/07
Members of the board TitleAgeSince
Director/Board Member 78 -
Director/Board Member 66 30/04/21
Chairman 64 -
More insiders
Date Price Change Volume
29/05/24 158.5 -0.94% 21 087
28/05/24 160 +0.95% 22,385
24/05/24 158.5 0.00% 38,871
23/05/24 158.5 0.00% 39,962
22/05/24 158.5 0.00% 26,985

Delayed Quote London S.E., May 29, 2024 at 04:35 pm

More quotes
Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.6 GBP
Average target price
5.037 GBP
Spread / Average Target
+214.79%
Consensus

Annual profits - Rate of surprise